Anthos and Novartis initiate LILAC-TIMI 76 trial for abelacimab in high-risk AF patients
The LILAC-TIMI 76 study is evaluating abelacimab's efficacy and safety in high-risk atrial fibrillation patients unsuitable for oral anticoagulation.
Phase III
Cardiology / Atrial Fibrillation
Status
Active
Sponsor
Anthos Therapeutics
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The LILAC-TIMI 76 trial is crucial as it evaluates a new treatment for high-risk atrial fibrillation patients who cannot use traditional anticoagulants. Success could shift treatment paradigms and affect market dynamics significantly.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial enrollment progress, interim results, and any announcements regarding efficacy endpoints.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.